Bellicum Pharmaceuticals Gross Profit

The latest gross profit for BLCM is $1.5M as of September 2023. That compares with $1.5M in the prior-year period — up 0.5% year over year. That is below the Healthcare sector average of $66B. Investors often review this figure alongside Bellicum Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, BLCM's gross profit moved from $1.5M to $1.5M — a 0.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bellicum Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, BLCM currently prints $1.5M for gross profit, while the sector average sits near $66B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Bellicum Pharmaceuticals's growth, margins, and balance sheet.

A gross profit figure of $1.5M for BLCM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $66B. Explore the charts below for those layers of context.

After noting BLCM's gross profit ($1.5M), review year-over-year change from $1.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.